knowledge -WSS

knowledge

author：Wikipedia 2025-10-01 15:38:59 - browse：43637

Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

WSS

Bernie brings in new pharma CEOs to talk drug prices

The Biogen Aduhelm mess could happen again

Why Novartis is going to walk from its acquisition of MorphoSys

What’s missing from the debate over nursing home staff minimums

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

Google and Epic fight stronger regulation of AI in health care

entertainment

knowledge

hotspot

Jerome Adams on the need for new antivirals for Covid

Devoted Health’s losses in Medicare Advantage persist

BioMarin wins approval for gene therapy to treat hemophilia A

A single Democrat is willing to weaken Medicare negotiation power

Guidelines to prevent youth baseball injuries need more muscle

Devoted Health’s losses in Medicare Advantage persist

BioMarin wins approval for gene therapy to treat hemophilia A

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Anesthesiologist group: stop taking Ozempic before surgery

Sanofi seeks simpler, safer CRISPR sickle cell cure

explore

Devoted Health’s losses in Medicare Advantage persist

The Biogen Aduhelm mess could happen again

Devoted Health’s losses in Medicare Advantage persist

Key House panel plots a new health care package

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Sanders adds drug shortage policies to pandemic preparedness bill

hotspot

knowledge

entertainment

entertainment